Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions

In vitro screening for pharmacological activity of existing drugs showed chloroquine and hydroxychloroquine to be effective against severe acute respiratory syndrome coronavirus 2. Oral administration of these compounds to obtain desired pulmonary exposures resulted in dose-limiting systemic toxicity in humans. However, pulmonary drug delivery enables direct and rapid administration to obtain higher local tissue concentrations in target tissue. In this work, inhalable formulations for thermal aerosolization of chloroquine and hydroxychloroquine were developed, and their physicochemical properties were characterized. Thermal aerosolization of 40 mg/mL chloroquine and 100 mg/mL hydroxychloroquine formulations delivered respirable aerosol particle sizes with 0.15 and 0.33 mg per 55 mL puff, respectively. In vitro toxicity was evaluated by exposing primary human bronchial epithelial cells to aerosol generated from Vitrocell. An in vitro exposure to 7.24 μg of chloroquine or 7.99 μg hydroxychloroquine showed no significant changes in cilia beating, transepithelial electrical resistance, and cell viability. The pharmacokinetics of inhaled aerosols was predicted by developing a physiologically based pharmacokinetic model that included a detailed species-specific respiratory tract physiology and lysosomal trapping. Based on the model predictions, inhaling emitted doses comprising 1.5 mg of chloroquine or 3.3 mg hydroxychloroquine three times a day may yield therapeutically effective concentrations in the lung. Inhalation of higher doses further increased effective concentrations in the lung while maintaining lower systemic concentrations. Given the theoretically favorable risk/benefit ratio, the clinical significance for pulmonary delivery of aerosolized chloroquine and hydroxychloroquine to treat COVID-19 needs to be established in rigorous safety and efficacy studies. Graphical abstract

[1]  H. Boushey,et al.  Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate – A Potential Treatment for COVID-19 , 2021, Journal of Allergy and Clinical Immunology.

[2]  A. Calise,et al.  Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study , 2020, BMC Infectious Diseases.

[3]  W. Jusko,et al.  Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[4]  H. Kerstjens,et al.  Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers , 2020, medRxiv.

[5]  D. Concordet,et al.  Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19 , 2020, International Journal of Antimicrobial Agents.

[6]  P. Lienau,et al.  Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat , 2020, Drug Metabolism and Disposition.

[7]  W. Haefeli,et al.  Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters , 2020, Pharmaceutics.

[8]  E. Goetghebeur,et al.  Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants , 2020, International Journal of Antimicrobial Agents.

[9]  M. Müller,et al.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.

[10]  P. Bhargava,et al.  Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 , 2020, International Journal of Infectious Diseases.

[11]  C. Yao,et al.  SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery , 2020, bioRxiv.

[12]  V. Calvez,et al.  Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  K. Rowland Yeo,et al.  Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling , 2020, Clinical pharmacology and therapeutics.

[14]  Jiang Liu,et al.  Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  H. Derendorf Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin , 2020, International Journal of Antimicrobial Agents.

[16]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[17]  J. Qiao,et al.  Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model , 2020, Acta Pharmaceutica Sinica B.

[18]  Susan Daniel,et al.  Coronavirus membrane fusion mechanism offers a potential target for antiviral development , 2020, Antiviral Research.

[19]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[20]  A. Kalil Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. , 2020, JAMA.

[21]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[22]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[24]  M. Peitsch,et al.  Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond , 2019, Critical reviews in toxicology.

[25]  R. Irizarry ggplot2 , 2019, Introduction to Data Science.

[26]  M. Peitsch,et al.  Application of a multi-layer systems toxicology framework for in vitro assessment of the biological effects of Classic Tobacco e-liquid and its corresponding aerosol using an e-cigarette device with MESH™ technology , 2019, Archives of Toxicology.

[27]  M. Brodlie,et al.  Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells , 2019, Journal of visualized experiments : JoVE.

[28]  Luo Zhang,et al.  Influence of Intranasal Drugs on Human Nasal Mucociliary Clearance and Ciliary Beat Frequency , 2018, Allergy, asthma & immunology research.

[29]  Julia Hoeng,et al.  A lung/liver-on-a-chip platform for acute and chronic toxicity studies. , 2018, Lab on a chip.

[30]  D. Gustafson,et al.  Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[31]  D. Oupický,et al.  Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[32]  Aleksandra Galetin,et al.  Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Michael Gertz,et al.  In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. , 2017, Molecular pharmaceutics.

[34]  Eleonore Fröhlich,et al.  Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds , 2016, Front. Pharmacol..

[35]  M. Jamei,et al.  A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins , 2015, The AAPS Journal.

[36]  M. Bolognesi,et al.  Lewis Acid‐Catalyzed Generation of CC and CN Bonds on π‐Deficient Heterocyclic Substrates , 2015 .

[37]  Bahman Asgharian,et al.  Thoracic and respirable particle definitions for human health risk assessment , 2013, Particle and Fibre Toxicology.

[38]  P. G. Jayathilake,et al.  Muco-ciliary transport: Effect of mucus viscosity, cilia beat frequency and cilia density , 2011 .

[39]  Patrick Poulin,et al.  Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.

[40]  Denis Wirtz,et al.  Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.

[41]  Trina A. Siebert,et al.  Influence of liquid-layer thickness on pulmonary surfactant spreading and collapse. , 2008, Biophysical journal.

[42]  Johannes Kornhuber,et al.  Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.

[43]  J. Widdicombe,et al.  Mechanisms of Acid and Base Secretion by the Airway Epithelium , 2006, The Journal of Membrane Biology.

[44]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[45]  R. Horobin,et al.  A predictive model for the selective accumulation of chemicals in tumor cells , 2005, European Biophysics Journal.

[46]  R. Tarran Regulation of airway surface liquid volume and mucus transport by active ion transport. , 2004, Proceedings of the American Thoracic Society.

[47]  R. Boucher,et al.  Polarized distribution of HCO3− transport in human normal and cystic fibrosis nasal epithelia , 2003, The Journal of physiology.

[48]  M. Andersen,et al.  PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS , 2002, Inhalation toxicology.

[49]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[50]  T. Speed,et al.  Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. , 1995, Journal of applied physiology.

[51]  B. Asgharian,et al.  A multiple-path model of particle deposition in the rat lung. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[52]  D. Cutler,et al.  Kinetics of chloroquine uptake into isolated rat hepatocytes. , 1993, Journal of pharmaceutical sciences.

[53]  W. Kreyling,et al.  Intraphagolysosomal pH in canine and rat alveolar macrophages: flow cytometric measurements. , 1992, Environmental health perspectives.

[54]  R. Day,et al.  Bioavailability of hydroxychloroquine tablets in healthy volunteers. , 1989, British journal of clinical pharmacology.

[55]  R. Day,et al.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. , 1988, British journal of clinical pharmacology.

[56]  G. Alván,et al.  The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. , 1987, British journal of clinical pharmacology.

[57]  B. Beermann,et al.  Disposition of chloroquine in man after single intravenous and oral doses. , 1983, British journal of clinical pharmacology.

[58]  Everett Ed,et al.  Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. , 1983 .

[59]  L. Salako,et al.  Tissue and blood concentrations of chloroquine following chronic administration in the rat , 1982, The Journal of pharmacy and pharmacology.

[60]  L. Salako,et al.  Kinetics of the distribution and elimination of chloroquine in the rat. , 1982, General pharmacology.

[61]  M. Frisk‐Holmberg,et al.  Chloroquine serum concentration and side effects: Evidence for dose‐dependent kinetics , 1979, Clinical pharmacology and therapeutics.

[62]  B Poole,et al.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Reijngoud,et al.  Chloroquine accumulation in isolated rat liver lysosomes , 1976, FEBS letters.

[64]  Walter Hayduk,et al.  Prediction of diffusion coefficients for nonelectrolytes in dilute aqueous solutions , 1974 .